Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR5 | P32302 | 15/20 | 0.74 |
| ▸ | LDHA | P00338 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PYGL | P06737 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3310747 | 0.85 | CXCR5 (1.00) | CXCR5 | |
| SCHEMBL3310224 | 0.83 | CXCR5 (0.53) | CXCR5LDHAKDM4EMEN1LMNA | |
| SCHEMBL3308985 | 0.80 | CXCR5 (0.73) | CXCR5 | |
| SCHEMBL3309864 | 0.78 | CXCR5 (1.00) | CXCR5 | |
| SCHEMBL3314239 | 0.78 | CXCR5 (0.69) | CXCR5 | |
| SCHEMBL3314175 | 0.78 | CXCR5 (0.72) | CXCR5PYGLCYP2C9 | |
| SCHEMBL10290187 | 0.76 | KMT2A (0.49) | LDHAKDM4EMEN1LMNAMAPT | |
| SCHEMBL3309293 | 0.75 | CXCR5 (1.00) | CXCR5LMNA | |
| SCHEMBL485604 | 0.74 | CXCR2 (0.51) | LDHAKDM4EMEN1LMNAMAPT | |
| SCHEMBL3303886 | 0.74 | CXCR5 (0.62) | CXCR5KDM4ELMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101679346-B | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI-AVENTIS (FR) | 2014-10-22 | — | — | CN | disclosed |
| US-8569535-B2 | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI (FR) | 2013-10-29 | — | — | US | disclosed |
| US-8569535-B2 | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI (FR) | 2013-10-29 | — | — | US | disclosed |
| US-8569535-B2 | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI (FR) | 2013-10-29 | — | — | US | disclosed |
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| CN-101679346-A | substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI AVENTIS | 2010-03-24 | — | — | CN | disclosed |
| WO-2008151211-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | CXCR5, CXCR1, CCR5 | CXCR5 1/4885LDHA 3631/4885KDM4E 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.